lifestyle.celebhomes.net
Home
Sample Page
Author:
Lexaria Bioscience Corp.
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
April 21, 2026
Lexaria’s New Animal Study Aims to Expand Valuable Intellectual Property
April 15, 2026
Lexaria Applauds Eli Lilly’s Foundayo(TM) Drug Approval
April 7, 2026
Lexaria to Begin New Human Clinical Study in GLP-1
April 1, 2026
Lexaria’s Robust Patent Portfolio Continues to Grow
March 26, 2026
Lexaria Announces Positive Final Results From Human Pilot Study #5
February 6, 2026
Lexaria Awarded Six Additional Patents
January 22, 2026
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
December 30, 2025
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 18, 2025
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 15, 2025